189 related articles for article (PubMed ID: 10895014)
1. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.
Mincheff M; Tchakarov S; Zoubak S; Loukinov D; Botev C; Altankova I; Georgiev G; Petrov S; Meryman HT
Eur Urol; 2000 Aug; 38(2):208-17. PubMed ID: 10895014
[TBL] [Abstract][Full Text] [Related]
2. In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile.
Mincheff M; Altankova I; Zoubak S; Tchakarov S; Botev C; Petrov S; Krusteva E; Kurteva G; Kurtev P; Dimitrov V; Ilieva M; Georgiev G; Lissitchkov T; Chernozemski I; Meryman HT
Crit Rev Oncol Hematol; 2001; 39(1-2):125-32. PubMed ID: 11418309
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
Todorova K; Ignatova I; Tchakarov S; Altankova I; Zoubak S; Kyurkchiev S; Mincheff M
Cancer Immun; 2005 Jan; 5():1. PubMed ID: 15641767
[TBL] [Abstract][Full Text] [Related]
4. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines.
Todorova K; Zoubak S; Mincheff M; Kyurkchiev S
Anticancer Res; 2005; 25(6C):4727-32. PubMed ID: 16334167
[TBL] [Abstract][Full Text] [Related]
5. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
[TBL] [Abstract][Full Text] [Related]
8. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
Salgaller ML; Lodge PA; McLean JG; Tjoa BA; Loftus DJ; Ragde H; Kenny GM; Rogers M; Boynton AL; Murphy GP
Prostate; 1998 May; 35(2):144-51. PubMed ID: 9568678
[TBL] [Abstract][Full Text] [Related]
9. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.
Mincheff M; Zoubak S; Altankova I; Tchakarov S; Makogonenko Y; Botev C; Ignatova I; Dimitrov R; Madarzhieva K; Hammett M; Pomakov Y; Meryman H; Lissitchkov T
Cancer Gene Ther; 2003 Dec; 10(12):907-17. PubMed ID: 14712317
[TBL] [Abstract][Full Text] [Related]
10. [The construction of recombinant plasmid with prostate-specific membrane antigen promoter controlling reporter gene expression].
Zeng H; Li H; Liao YC; Li X; Wu Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):169-71. PubMed ID: 15807257
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines: an active immunization strategy for prostate cancer.
Wolchok JD; Gregor PD; Nordquist LT; Slovin SF; Scher HI
Semin Oncol; 2003 Oct; 30(5):659-66. PubMed ID: 14571413
[TBL] [Abstract][Full Text] [Related]
12. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific membrane antigen: current and future utility.
Gregorakis AK; Holmes EH; Murphy GP
Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
Slovin SF; Kehoe M; Durso R; Fernandez C; Olson W; Gao JP; Israel R; Scher HI; Morris S
Vaccine; 2013 Jan; 31(6):943-9. PubMed ID: 23246260
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro.
Kraaij R; van Rijswijk AL; Oomen MH; Haisma HJ; Bangma CH
Prostate; 2005 Feb; 62(3):253-9. PubMed ID: 15389777
[TBL] [Abstract][Full Text] [Related]
18. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
[TBL] [Abstract][Full Text] [Related]
19. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
20. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
Gregor PD; Wolchok JD; Turaga V; Latouche JB; Sadelain M; Bacich D; Heston WD; Houghton AN; Scher HI
Int J Cancer; 2005 Sep; 116(3):415-21. PubMed ID: 15800947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
